Related Experiment Video
Updated: Oct 10, 2026

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
Published on: February 21, 2014
Effects of estrogen on global gene expression: identification of novel targets of estrogen action
A H Charpentier1, A K Bednarek, R L Daniel
1Department of Carcinogenesis, University of Texas, M. D. Anderson Cancer Center, Smithville 78957, USA.
Abstract:
The important role played by the sex hormone estrogen in disease and physiological processes has been well documented. However, the mechanisms by which this hormone elicits many of its normal as well as pathological effects are unclear. To identify both known and unknown genes that are regulated by or associated with estrogen action, we performed serial analysis of gene expression on estrogen-responsive breast cancer cells after exposure to this hormone. We examined approximately 190,000 mRNA transcripts and monitored the expression behavior of 12,550 genes. Expression levels for the vast majority of those transcripts were observed to remain constant upon 17beta estradiol (E2) treatment. Only approximately 0.4% of the genes showed an increase in expression of > or =3-fold by 3 h post-E2 treatment. We cloned five novel genes (E2IG1-5), which were observed up-regulated by the hormonal treatment. Of these the most highly induced transcript, E2IG1, appears to be a novel member of the family of small heat shock proteins. The E2IG4 gene is a new member of the large family of leucine-rich repeat-containing proteins. On the basis of architectural and domain homology, this gene appears to be a good candidate for secretion in the extracellular environment and, therefore, may play a role in breast tissue remodeling and/or epithelium-stroma interactions. Several interesting genes with a potential role in the regulation of cell cycle progression were also identified to increase in expression, including Pescadillo and chaperonin CCT2. Two putative paracrine/autocrine factors of potential importance in the regulation of the growth of breast cancer cells were identified to be highly up-regulated by E2: stanniocalcin 2, a calcium/phosphate homeostatic hormone; and inhibin-beta B, a TGF-beta-like factor. Interestingly, we also determined that E2IG1 and stanniocalcin 2 were exclusively overexpressed in estrogen-receptor-positive breast cancer lines, and thus they have the potential to serve as breast cancer biomarkers. This data provides a comprehensive view of the changes induced by E2 on the transcriptional program of human E2-responsive cells, and it also identifies novel and previously unsuspected gene targets whose expression is affected by this hormone.
Insights
Estrogen
Area of Science:
- Molecular Biology
- Genomics
- Endocrinology
Background:
- Estrogen plays a critical role in physiological and pathological processes, but its precise mechanisms of action are not fully understood.
- Identifying genes regulated by estrogen is crucial for understanding its effects in diseases like breast cancer.
Purpose of the Study:
- To identify novel genes regulated by estrogen action in human breast cancer cells.
- To comprehensively analyze the transcriptional changes induced by estrogen.
Main Methods:
- Serial analysis of gene expression (SAGE) was performed on estrogen-responsive breast cancer cells.
- Approximately 190,000 mRNA transcripts and 12,550 genes were analyzed after 17beta-estradiol (E2) treatment.
Main Results:
- Only 0.4% of genes showed a significant increase (> or =3-fold) in expression within 3 hours of E2 treatment.
- Five novel estrogen-induced genes (E2IG1-5) were identified, including E2IG1 (small heat shock protein family) and E2IG4 (leucine-rich repeat-containing protein).
- Estrogen-responsive genes involved in cell cycle regulation (Pescadillo, CCT2) and growth factors (stanniocalcin 2, inhibin-beta B) were identified. E2IG1 and stanniocalcin 2 were overexpressed in estrogen-receptor-positive breast cancer cells.
Conclusions:
- Estrogen significantly alters the transcriptional program of responsive cells, revealing novel gene targets.
- E2IG1 and stanniocalcin 2 show potential as biomarkers for estrogen-receptor-positive breast cancer.

